摘要
目的探讨P53、P16和Bcl-2蛋白在非小细胞肺癌组织中的表达及其临床意义。方法应用免疫组化技术,检测原发性非小细胞肺癌组织60例和距离肿瘤边缘5 cm以上的癌旁正常肺组织18例的P53、P16和Bcl-2蛋白的表达。结果 P53、P16和Bcl-2蛋白在非小细胞肺癌组织中的表达与癌旁正常肺组织比较,差异有显著性(Hc=10.003~14.783,P〈0.01)。非小细胞肺癌组织P53、P16蛋白的表达与肿瘤的分化程度有关(Hc=15.119、19.078,P〈0.01),Bcl-2蛋白的表达与肿瘤的分化程度、TNM分期及淋巴结转移有关(Hc=16.271、13.205,u=2.849,P〈0.01)。非小细胞肺癌组织的P53与P16蛋白表达之间呈负相关(rs=-0.437,P〈0.01)。结论 P53、P16及Bcl-2蛋白的表达失衡与非小细胞肺癌的发生发展密切相关。
Objective To explore the expressions of P53,P16 and Bcl-2 in non-small cell lung cancer(NSLC) and their clinical significance. Methods Immunohistochemical technique was used to detect the expressions of P53,P16 and Bcl-2 in cancer tissue of 60 primary NSCLC patients,and 18 normal tissue samples that 5 cm away from the border of the cancer. ResultsThe differences of expressions of P53,P16 and Bcl-2 between cancer tissue and paraneoplastic tissue were significant(Hc=10.003-14.783,P〈0.01),The expressions of P53 and P16 were related to differentiation of the cancer(Hc=15.119,19.078;P〈0.01),and that of Bcl-2 was related to differentiation,TNM stage and lymphatic metastasis(Hc=16.271,13.205;u=2.849;P〈0.01).The expression of P53 was negatively correlated with P16(rs=-0.437,P〈0.01). Conclusion Unbalance of the expressions of P53,P16 and Bcl-2 is closely associated with the occurrence and development of non-small cell lung cancer.
出处
《齐鲁医学杂志》
2011年第4期302-304,共3页
Medical Journal of Qilu
基金
国家自然科学基金资助项目(60973158)